Cannabis for Chronic Pain

Chronic pain is defined as pain persisting for three months or more, often outlasting the original injury or underlying condition. Unlike acute pain, which serves as a useful biological warning signal, chronic pain reflects a pathological state in which the nervous system continues to generate pain signals long after tissue damage has healed. It affects every aspect of daily function, including sleep, cognition, emotional health, and social participation — and remains one of the most costly and undertreated medical conditions worldwide.

Chronic pain encompasses a broad spectrum of conditions. Neuropathic pain — caused by nerve damage or dysfunction — includes diabetic peripheral neuropathy, postherpetic neuralgia, HIV-associated neuropathy, and chemotherapy-induced peripheral neuropathy. Nociceptive chronic pain includes osteoarthritis, rheumatoid arthritis, and chronic low back pain. Central sensitization syndromes, where the central nervous system itself becomes hypersensitized to pain signals, include fibromyalgia and complex regional pain syndrome (CRPS). Conventional treatments — NSAIDs, opioids, anticonvulsants, antidepressants — provide inadequate relief for a substantial proportion of patients, driving interest in cannabis as an adjunctive or alternative option. Explore all medical conditions covered in our medical cannabis guide.

The endocannabinoid system (ECS) is the body’s own pain-modulating network, and it is the primary target through which cannabis exerts its analgesic effects. The ECS consists of endogenous cannabinoids (anandamide and 2-arachidonoylglycerol, or 2-AG), cannabinoid receptors (CB1 and CB2), and the enzymes that synthesize and degrade these molecules. Understanding the ECS architecture is essential to understanding why cannabis can be effective — and why its effects vary substantially between individuals.

THC and CB1: Descending Pain Inhibition

CB1 receptors are densely expressed in the central nervous system, with particularly high concentrations in regions critical to pain processing: the periaqueductal gray (PAG), the rostral ventromedial medulla (RVM), the spinal cord dorsal horn, and the thalamus. THC binds to these CB1 receptors and activates the descending inhibitory pain pathway — the brain’s own system for suppressing pain signals before they reach full conscious perception. This mechanism is directly analogous to how the body uses endogenous opioids, which explains the significant analgesic overlap between cannabinoids and opioids and the well-documented opioid-sparing effects observed in chronic pain patients using medical cannabis.

CBD, CB2, TRPV1, and Adenosine

CBD operates through multiple complementary mechanisms. At CB2 receptors, concentrated in immune cells and peripheral nerve tissue, CBD reduces pro-inflammatory cytokine production — a critical mechanism for inflammatory pain conditions like rheumatoid arthritis. CBD also acts as an antagonist at TRPV1 (transient receptor potential vanilloid 1), a receptor that functions as a thermosensor and pain detector. By desensitizing TRPV1, CBD can reduce both thermal and inflammatory pain sensitivity. Additionally, CBD modulates adenosine signaling by inhibiting its cellular uptake, producing downstream anti-inflammatory and analgesic effects throughout the peripheral and central nervous systems. Learn more about myrcene, the terpene most associated with pain relief and muscle relaxation in cannabis.

The FAAH-Anandamide Pathway

One of CBD’s most important indirect analgesic mechanisms involves the enzyme FAAH (fatty acid amide hydrolase), which normally degrades anandamide — the endogenous cannabinoid sometimes called the “bliss molecule.” By inhibiting FAAH, CBD prevents anandamide breakdown, allowing higher concentrations of this endogenous painkiller to remain active in synapses. Researchers have observed that many chronic pain patients show depleted anandamide levels, a phenomenon linked to Clinical Endocannabinoid Deficiency (CECD). Restoring anandamide tone through FAAH inhibition represents one mechanism by which CBD may provide sustained pain relief without direct psychoactivity.

The scientific literature on cannabis and chronic pain represents the most robust body of evidence for any medical cannabis application. Multiple systematic reviews, meta-analyses, and controlled trials have been published, and while study quality varies, the overall picture is consistently supportive — particularly for neuropathic pain and pain associated with neurological conditions like multiple sclerosis.

The National Academies of Sciences 2017 Report

The most widely cited summary of cannabis research is the 2017 report from the National Academies of Sciences, Engineering, and Medicine, “The Health Effects of Cannabis and Cannabinoids.” After reviewing more than 10,000 scientific abstracts, the committee concluded there is “conclusive or substantial evidence” that cannabis is effective for treating chronic pain in adults. This was the highest evidence rating applied in the entire report and was based on a body of randomized controlled trials, systematic reviews, and meta-analyses. The committee noted that this evidence was strongest for neuropathic pain.

Neuropathic Pain: The Strongest Evidence

Multiple randomized controlled trials support cannabis for neuropathic pain. A 2010 Canadian Medical Association Journal study found that vaporized 9.4% THC cannabis significantly reduced chronic neuropathic pain intensity, improved sleep, and was well-tolerated by patients who had failed other treatments. A 2013 meta-analysis covering 38 RCTs concluded that cannabinoids provided significant pain relief in neuropathic conditions. Sativex, a 1:1 THC:CBD oromucosal spray, has received regulatory approval in the United Kingdom and Canada specifically for neuropathic pain in multiple sclerosis — the first cannabis-derived medicine approved for pain by any major regulatory agency. See our guide on cannabis for multiple sclerosis for more on this approval.

Fibromyalgia and Real-World Evidence

A prospective study by Aviram & Samuelly-Leichtag (2017) followed fibromyalgia patients using medical cannabis and found over 80% reported significant pain improvement, with reduced reliance on conventional analgesics including opioids. A large retrospective Israeli study of 1,176 chronic pain patients (Israel, 2016) found that 70% reported at least moderate improvement in their condition, with 60% reporting improved quality of life. These real-world evidence figures align with clinical trial data and support the growing integration of medical cannabis into multidisciplinary pain management programs. Explore more in our fibromyalgia guide.

Most clinical researchers and cannabis physicians recommend starting with a CBD-dominant or balanced product, then titrating THC upward as needed based on individual response. This approach minimizes psychoactive side effects while leveraging CBD’s anti-inflammatory properties from the outset. Pure high-THC products can be effective for severe neuropathic or cancer-related pain but carry higher risk of tolerance development and cognitive effects with long-term use.

Strain selection should be guided by pain type, time of day, and psychoactivity tolerance. The following strains are frequently recommended by medical cannabis patients and clinicians for pain management. Always consult a dispensary professional or cannabis-certified physician for personalized guidance.

• OG Kush — Hybrid — high myrcene, strong body relaxation, excellent for evening pain relief
• Granddaddy Purple — Indica — deep body sedation, myrcene + linalool terpenes, best for nighttime use
• ACDC — CBD-dominant (20:1 CBD:THC) — daytime pain relief without impairment
• Harlequin — CBD-dominant (5:2 CBD:THC) — balanced, clear-headed pain management
• Blue Dream — Hybrid — mild body relaxation with functional energy, suitable for daytime pain
• Northern Lights — Indica — deep body relaxation, classic choice for musculoskeletal pain and insomnia

Browse All 440+ Strains →

For chronic pain patients, sublingual tinctures offer the best combination of onset speed and dosing precision, making them the most commonly recommended starting point by cannabis physicians. Topicals are ideal for patients with arthritic or localized pain who want therapeutic benefit without any psychoactive effects or concerns about drug testing. See our drug test guide if testing is a concern alongside medical cannabis use. If pain flares unpredictably, keeping a vaporizer available for breakthrough pain alongside a baseline tincture regimen is a well-established approach in medical cannabis care.

Chronic pain is the most widely recognized qualifying condition across U.S. state medical cannabis programs. More than 35 states have active medical cannabis programs, and the majority list “chronic pain,” “intractable pain,” or “severe pain” among their qualifying conditions. States where chronic pain is an explicit qualifying condition include California, Florida, Ohio, Michigan, Pennsylvania, New York, Arizona, and New Jersey, among others. In states that do not list it explicitly, many allow physician discretion for serious conditions where pain is a primary symptom.

Some states require a documented history of failed conventional treatment before approving cannabis for pain. Others require specific pain diagnoses rather than accepting general chronic pain as a standalone qualifier. Always consult the official program website for your state, or work with a cannabis-certified physician who can navigate the certification process and ensure your documentation meets state requirements.

Explore your state’s cannabis laws: California — Florida — Ohio — Michigan — Pennsylvania — All 50 States →